TN2011000051A1 - Pyrrolidin-2-ones as hdm2 ligands - Google Patents
Pyrrolidin-2-ones as hdm2 ligandsInfo
- Publication number
- TN2011000051A1 TN2011000051A1 TN2011000051A TN2011000051A TN2011000051A1 TN 2011000051 A1 TN2011000051 A1 TN 2011000051A1 TN 2011000051 A TN2011000051 A TN 2011000051A TN 2011000051 A TN2011000051 A TN 2011000051A TN 2011000051 A1 TN2011000051 A1 TN 2011000051A1
- Authority
- TN
- Tunisia
- Prior art keywords
- formula
- compounds
- pyrrolidin
- ones
- disease
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000003183 carcinogenic agent Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2009/006670 WO2010028862A1 (fr) | 2008-09-15 | 2009-09-15 | Pyrrolidine-2-ones comme ligands de hdm2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000051A1 true TN2011000051A1 (en) | 2012-09-05 |
Family
ID=55024365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TN2011000051A TN2011000051A1 (en) | 2009-09-15 | 2011-01-28 | Pyrrolidin-2-ones as hdm2 ligands |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2011000051A1 (fr) |
-
2011
- 2011-01-28 TN TN2011000051A patent/TN2011000051A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008034039A3 (fr) | Tétrahydro-isoquinolines innovantes | |
| EA201100483A1 (ru) | Новые пирролидин-2-оны в качестве hdm2 лигандов | |
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| WO2008128038A3 (fr) | Procédés et compositions permettant de traiter les dysfonctionnements cardiaques | |
| PH12016502132B1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
| MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
| PH12013500011A1 (en) | Napht-2-ylacetic acid derivatives to treat aids | |
| UA105018C2 (uk) | Акриламідопохідні, застосовні як інгібітори переходу мітохондріальної проникності | |
| PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
| EA201391644A1 (ru) | Частично насыщенные трициклические соединения и способы их получения и применения | |
| MX2013004329A (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
| MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| MX2013008296A (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| GB201001602D0 (en) | Oligopeptidic compounds and uses therof | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| MY179527A (en) | Catecholamine derivatives useful for the treatment of parkinson's disease | |
| PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| MX2014003449A (es) | Heterociclocarbonilaminotiazoles, preparaciones cosmeticas o dermatologicas que contienen los mismos y su uso para el control y la profilaxis de pigmentacion indeseada de la piel. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2010000223A (es) | Compuestos de triazina novedosos para el tratamiento de cancer. | |
| MX2015005733A (es) | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |